Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
Eargo's peak revenue was $69.2M in 2020. The peak quarterly revenue was $22.9M in 2021(q2).
Eargo's revenue increased from $32.8m in 2019 to $37.2M currently. That's a 13.6% change in annual revenue.
| Fiscal year / year | Eargo revenue |
|---|---|
| 2019 | $32.8M |
| 2020 | $69.2M |
| 2021 | $32.1M |
| 2022 | $37.2M |
How accurately did Eargo's revenue projections match actual performance?
Eargo saw the greatest revenue growth in 2020, when revenue increased by 110.9%.
Eargo had the lowest revenue growth in 2021, when revenue changed by -53.55%.
| Year | Eargo growth |
|---|---|
| 2020 | 111%↑ |
| 2021 | -54%↓ |
| 2022 | 16%↑ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2020 | - | - | $18.2M | $22.4M |
| 2021 | $22.0M | $22.9M | ($22.9M) | $10.1M |
| 2022 | $9.2M | $7.2M | $7.9M | $12.9M |
| 2023 | $11.8M | $8.1M | $8.3M | - |
Do you work at Eargo?
Is Eargo transparent about its revenue structure?
| CEO | Christian Gormsen |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 150 |
| Date Founded | 2012 |
| Headquarters | San Jose, California |
| Number of Locations | 2 |
| Revenue | $37.2M |
| Net Income | -$157,487,000 |
| Gross Proft | $14.3M (2022) |
| Tax Rate | -0.0% |
| Total Assets | $132,078,000 |
| Ticker | EAR |
Eargo received early financing of $13.6M on 2015-06-25.
| Series | Round size | Date |
|---|---|---|
| Series A | $13.6M | 06/2015 |
| Series B | $25M | 12/2015 |
| Series C | $45M | 10/2017 |
| Series D | $52M | 03/2019 |
| Series E | $81.6M | 07/2020 |
| Investors | Security type |
|---|---|
| Birchmere Ventures | Series A |
| Farzad Nazem | Series A |
| Red Sea Ventures | Series A |
| Dolby Family Ventures | Series A |
| Maveron | Series A |
| Crosslink Capital | Series A |
| Montage Ventures | Series A |
| Pierre Lamond | Series A |
| Peterson Ventures | Series A |
| Dolby Family Ventures | Series B |
| StartX | Series B |
| New Enterprise Associates (NEA) | Series B |
| Maveron | Series B |
| Nan Fung Life Sciences | Series C |
| The Charles Schwab Corporation | Series C |
| New Enterprise Associates (NEA) | Series C |
| Maveron | Series C |
| Nan Fung Life Sciences | Series D |
| New Enterprise Associates (NEA) | Series D |
| Maveron | Series D |
| Schwab Institutional | Series D |
| Future Fund | Series D |
| Nan Fung Life Sciences | Series E |
| New Enterprise Associates (NEA) | Series E |
| Longitude Capital | Series E |
| Charles and Helen Schwab Foundation | Series E |
| Gilde Healthcare | Series E |
Eargo's top competitor, UnitedHealth Group, earned an annual revenue of $400.3B.
Eargo's smallest competitor is Locus with revenue of $230.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Boston Scientific | $60,291 | $16.7B | 36,000 | 873 |
| McKesson | $51,976 | $309.0B | 80,000 | 455 |
| Walgreens | $31,612 | - | 210,500 | 20,583 |
| UnitedHealth Group | $51,208 | $400.3B | 300,000 | 9,768 |
| Intersect ENT | $67,446 | $106.7M | 393 | - |
| LA Fitness | $26,931 | $2.1B | 13,387 | 1 |
| Owens & Minor | $38,357 | $10.7B | 17,900 | 671 |
| Alphabet | $58,794 | $350.0B | 156,301 | 5 |
| VF | $40,146 | $10.5B | 50,000 | 1,230 |
| Danaher | $65,463 | $23.9B | 80,000 | 1,844 |
Zippia gives an in-depth look into the details of Eargo, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Eargo. The employee data is based on information from people who have self-reported their past or current employments at Eargo. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Eargo. The data presented on this page does not represent the view of Eargo and its employees or that of Zippia.
Eargo may also be known as or be related to EARGO, INC., Eargo, Eargo Hearing, Inc. and Eargo, Inc.